New hope for tough leukemia: dasatinib tested after standard therapy fails

NCT ID NCT06055621

Recruiting now Disease control Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing the drug dasatinib alone in adults with acute myeloid leukemia (AML) whose cancer did not respond to the usual combination of venetoclax and azacitidine. The main goal is to see if dasatinib can shrink the leukemia after two months of treatment. About 35 people will take dasatinib daily for up to 3 months, and doctors will check their blood and bone marrow for signs of remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dasatinib (a targeted cancer drug taken daily by mouth)
What this could lead to: If it works, this could offer a new treatment option for AML patients who have not responded to standard therapy.
What could go wrong: This is a small, early-phase trial with only 35 participants. It may not work for everyone, and dasatinib can cause side effects like fluid retention or heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Institut Paoli Calmettes
RECRUITING

Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.